Professional Information for AMBROTOSE® COMPLEX POWDER

COMPLEMENTARY MEDICINE: COMBINATION PRODUCT
This unregistered medicine has not been evaluated by SAHPRA for its quality, safety or intended use.

SCHEDULING STATUS
S0

1. NAME OF THE MEDICINE
AMBROTOSE® COMPLEX POWDER

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each scoop contains:

Ambrotose® Complex	2 g
providing *Larix laricina* (Du Roi) K. Koch or *Larix occidentalis* Nutt. (Larch Arabinogalactan)	(0,96 g)
Manapol® Aloe vera (L.) Burm.f. (Aloe) [inner leaf gel, 415:1 extract, providing 83 g fresh herb equivalent]	(0,2 g)
Astragalus gummifer Labill. (Tragacanth)	(0,2 g)
Anogeissus latifolia (Roxb. ex DC.) Wall. ex Guillem. & Perr. (Ghatti gum)	(0,2 g)
Oryza sativa L. (Rice starch) [seed powder]	(0,24 g)
Glucosamine hydrochloride	(0,2 g)

Sugar free.
This product does not contain any excipients (see section 6.1).

3. PHARMACEUTICAL FORM
Powder.
Off-white to pale beige free flowing powder.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications
AMBROTOSE® COMPLEX POWDER is a combination complementary medicine intended to assist and provide support for the immune system.

4.2 Posology and method of administration
Adults: Take 1 scoop (2 grams) with a glass of water or juice, twice daily.
Do not exceed the recommended dosage.

MANNATECH®

4.3 Contraindications

- Hypersensitivity to Ambrotose® Complex (see section 2) or to any of the excipients listed in section 6.1.
- Abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease (e.g. Crohn's disease or ulcerative colitis), abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes, haemorrhoids or diarrhoea.
- Pregnancy or lactation.

4.4 Special warnings and precautions for use

AMBROTOSE® COMPLEX POWDER might interfere with blood glucose control during and after surgical procedures. Patients should be advised to discontinue AMBROTOSE® COMPLEX POWDER at least 2 weeks prior to any surgical procedures.

Patients with faecal impaction or symptoms such as abdominal pain, nausea, vomiting or fever should consult a health care provider prior to use.

Patients with a cardiac or kidney disorder, should consult a health care provider prior to use.

If abdominal pain, cramps, spasms and/or diarrhoea is experienced after taking AMBROTOSE® COMPLEX POWDER, patients should stop taking AMBROTOSE® COMPLEX POWDER or reduce the dose.

4.5 Interaction with other medicines and other forms of interaction

Cardiac or diuretic medicines
Patients taking cardiac medicines (e.g. cardiac glycosides or antidysrhythmic medicines), thiazide diuretics, corticosteroids, liquorice root, or other medicines or health products that may aggravate electrolyte imbalance, should consult with a health care provider prior to use.

Anticoagulant or antiplatelet medicines:
AMBROTOSE® COMPLEX POWDER may potentiate the effects of anticoagulant and antiplatelet medicines or herbal supplements with blood thinning effects.

4.6 Fertility, pregnancy and lactation

AMBROTOSE® COMPLEX POWDER should not be used during pregnancy and lactation (see section 4.3).

4.7 Effects on ability to drive and use machines

AMBROTOSE® COMPLEX POWDER is unlikely to affect the ability to drive and use machines.

4.8 Undesirable effects

Immune system disorders:
Less frequent: hypersensitivity reactions.

Gastrointestinal disorders:
Less frequent: abdominal pain and cramps, bloating, flatulence.

Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of AMBROTOSE® COMPLEX POWDER is important. It allows continued monitoring of the benefit/risk balance of AMBROTOSE® COMPLEX POWDER. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the **"Adverse Drug Reaction Reporting Form"**, found online under SAHPRA's publications: https://www.sahpra.org.za/Publications/Index/8

4.9 Overdose

In overdose, side effects can be precipitated and/or be of increased severity. See section 4.8.
In the event of overdose, treatment should be symptomatic and supportive.

5. PHARMACOLOGICAL PROPERTIES

Category and class: D 33.7 Combination Product.

Mechanism of action:
Aloe has anti-inflammatory, antioxidant, detoxification and immune-boosting properties.
Larch arabinogalactan has immune-boosting properties.
When ingested, the bulk of tragacanth stretches the intestinal wall, increasing peristalsis. It increases stool weight and decreases gastrointestinal (GI) transit time.
Glucosamine hydrochloride has anti-inflammatory and immune-boosting properties and helps to maintain healthy cartilage or joint health.
Rice starch has antioxidant properties.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

None.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

18 months.

6.4 Special precautions for storage

Store at or below 25 °C, in a dry place.
Keep the bottle tightly closed.
Do not use if inner seal is missing or broken.

6.5 Nature and contents of container

HDPE container with a PP cap containing 100 g powder.

6.6 Special precautions for disposal and other handling

No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

LeBasi Pharmaceuticals (Pty) Ltd
San Domenico Building, Ground Floor, Unit 6
10 Church Street
Durbanville, 7551

8. REGISTRATION NUMBER

Will be allocated by SAHPRA upon registration.

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Will be allocated by SAHPRA upon registration.

10. DATE OF REVISION OF THE TEXT

September 2021.

MANNATECH®